PhoreMost Limited, the Cambridge-based oncology biotech, has announced its lead drug candidate, PMC-001, a next-generation small molecule microtubule targeting agent (MTA) designed to treat both primary and secondary brain cancers. The company is preparing regulatory filings ahead of first-in-human clinical trials.
ProBioGen, the Berlin-based contract development and manufacturing organisation (CDMO), has appointed Dr Simon Johannes Bulling, PhD, as Chief Operating Officer (COO). The appointment signals a strategic intensification of the company’s operational ambitions across biologics, viral vectors, vaccines, and cell and gene therapies.
Epigenica AB, a Swedish biotechnology company specialising in epigenetic analysis tools, has entered into a formal agreement with the National Genomics Infrastructure (NGI) in Stockholm, marking a significant milestone in the commercial rollout of its EpiFinder™ platform. NGI Stockholm has become the first certified core laboratory and service provider globally to offer the EpiFinder suite, […]
Medix Biochemica, a Finland-based supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has announced a Board-approved $5 million investment to significantly expand its recombinant antigen and cell culture technology capabilities across two facilities, in Espoo, Finland, and St. Louis, Missouri.
German biotechnology company T-CURX has announced the acquisition of Pantherna Therapeutics, a move that brings together two complementary technology platforms and positions the combined entity as the first European biotech to integrate proprietary CAR-T and lipid nanoparticle (LNP) technologies under a single roof.
Cirena Inc., the Boulder, Colorado-based RNA synthesis company, has entered into a licensing agreement with Agilent Technologies, Inc. to access validated long RNA purification technology – a move that could significantly improve the consistency and scalability of synthetic RNA constructs used in genome editing and functional genomics research.
The Society of Laboratory Automation and Screening (SLAS) held its 2026 Europe Conference and Exhibition in Vienna, Austria, from 19 to 21 May, welcoming more than 1,500 registrants from over 30 countries alongside 137 exhibitors. The event had originally been planned for spring 2020 before being postponed.
CellCarta, the Montreal-based contract research organisation (CRO), has announced a strategic partnership with Sonic Healthcare USA, Inc. (SHUAS) that positions the company to bridge the critical gap between companion diagnostic (CDx) regulatory approval and broad commercial deployment across the United States.
Werfen, a global leader in specialised diagnostics, has announced a strategic collaboration with Oxford Nanopore Technologies to validate Werfen’s transplant assay portfolios for use on Oxford Nanopore’s sequencing platforms. The agreement builds on an initial collaboration between the two companies that began in 2020. The partnership combines Werfen’s high-precision transplant assays with Oxford Nanopore’s nanopore-based […]
RareLabs, a division of AlphaRose Therapeutics, has made its public debut with a modality-agnostic drug discovery platform that uses artificial intelligence and robotics to compress rare-disease treatment timelines from years to weeks. The Austin, Texas-based lab simultaneously announced the appointment of Dr Rob Freishtat as Chief Executive Officer.
August 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.